Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.

@article{GruvbergerSaal2007EstrogenRB,
  title={Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.},
  author={Sofia K. Gruvberger-Saal and P{\"a}r-Ola Bendahl and Lao H. Saal and Mervi Laakso and Cecilia Hegardt and Patrik Ed{\'e}n and Carsten Peterson and Per Malmstr{\"o}m and Jorma Isola and {\AA}ke Borg and M{\aa}rten Fern{\"o}},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2007},
  volume={13 7},
  pages={1987-94}
}
PURPOSE Endocrine therapies, such as tamoxifen, are commonly given to most patients with estrogen receptor (ERalpha)-positive breast carcinoma but are not indicated for persons with ERalpha-negative cancer. The factors responsible for response to tamoxifen in 5% to 10% of patients with ERalpha-negative tumors are not clear. The aim of the present study was to elucidate the biology and prognostic role of the second ER, ERbeta, in patients treated with adjuvant tamoxifen. EXPERIMENTAL DESIGN We… CONTINUE READING